Technical Details:
High risk Human Papillomavirus (HPV) infection is a common cause of cervical cancer. Researchers at JHU have found that vaccination with the N terminus of HPV16 and bovine papillomavirus 1 can induce cross neutralizing antibodies that inhibit in vitro generated pseudovirus infection of both cutaneous and genital types that infect both humans and animals.
Looking for Partners:
The invention could be developed into a simple protein-based vaccine to broadly prevent genital and cutaneous papillomavirus infections. The fact that the vaccination appears to have such a wide spectrum of activity against animal papillomavirus suggests that it could be developed for veterinarian use as well.